BRPI9912974B8 - conjugados de peg-urato oxidase e seu uso - Google Patents

conjugados de peg-urato oxidase e seu uso

Info

Publication number
BRPI9912974B8
BRPI9912974B8 BRPI9912974A BR9912974A BRPI9912974B8 BR PI9912974 B8 BRPI9912974 B8 BR PI9912974B8 BR PI9912974 A BRPI9912974 A BR PI9912974A BR 9912974 A BR9912974 A BR 9912974A BR PI9912974 B8 BRPI9912974 B8 BR PI9912974B8
Authority
BR
Brazil
Prior art keywords
peg
urate oxidase
urate
conjugates
poly
Prior art date
Application number
BRPI9912974A
Other languages
English (en)
Portuguese (pt)
Other versions
BR9912974A (pt
BRPI9912974B1 (pt
Inventor
L Williams David
G P Saifer Mark
R Sherman Merry
S Hershfield Michael
J Kelly Susan
Original Assignee
Univ Duke
Mountain View Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke, Mountain View Pharmaceuticals Inc filed Critical Univ Duke
Publication of BR9912974A publication Critical patent/BR9912974A/pt
Publication of BRPI9912974B1 publication Critical patent/BRPI9912974B1/pt
Publication of BRPI9912974B8 publication Critical patent/BRPI9912974B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI9912974A 1998-08-06 1999-08-02 conjugados de peg-urato oxidase e seu uso BRPI9912974B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13039298A 1998-08-06 1998-08-06
PCT/US1999/017514 WO2000007629A2 (en) 1998-08-06 1999-08-02 Peg-urate oxidase conjugates and use thereof

Publications (3)

Publication Number Publication Date
BR9912974A BR9912974A (pt) 2001-05-08
BRPI9912974B1 BRPI9912974B1 (pt) 2015-08-25
BRPI9912974B8 true BRPI9912974B8 (pt) 2021-05-25

Family

ID=22444494

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI9912974A BRPI9912974B8 (pt) 1998-08-06 1999-08-02 conjugados de peg-urato oxidase e seu uso
BRPI9917760A BRPI9917760B8 (pt) 1998-08-06 1999-08-02 método para isolar uma forma tetramérica de uricase a partir de uma solução de uricase purificada

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI9917760A BRPI9917760B8 (pt) 1998-08-06 1999-08-02 método para isolar uma forma tetramérica de uricase a partir de uma solução de uricase purificada

Country Status (13)

Country Link
EP (1) EP1100542B1 (cg-RX-API-DMAC7.html)
JP (3) JP5183836B2 (cg-RX-API-DMAC7.html)
KR (2) KR100614212B1 (cg-RX-API-DMAC7.html)
AU (1) AU770014B2 (cg-RX-API-DMAC7.html)
BR (2) BRPI9912974B8 (cg-RX-API-DMAC7.html)
CZ (1) CZ303751B6 (cg-RX-API-DMAC7.html)
HU (2) HU226294B1 (cg-RX-API-DMAC7.html)
IL (3) IL141220A0 (cg-RX-API-DMAC7.html)
NZ (1) NZ509595A (cg-RX-API-DMAC7.html)
PL (2) PL220873B1 (cg-RX-API-DMAC7.html)
RU (3) RU2246318C2 (cg-RX-API-DMAC7.html)
TW (1) TW570981B (cg-RX-API-DMAC7.html)
WO (1) WO2000007629A2 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2158923B1 (en) 1998-08-06 2013-02-27 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
BRPI9912974B8 (pt) * 1998-08-06 2021-05-25 Univ Duke conjugados de peg-urato oxidase e seu uso
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
NZ509633A (en) 1998-08-06 2003-04-29 Univ Duke A recombinant chimeric PEG-uricase with a long circulatory life and reduced immunogenicity
AU2006203252B8 (en) * 2000-02-10 2009-06-18 Duke University Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
CA2404737C (en) 2000-04-03 2010-06-29 Santen Pharmaceutical Co., Ltd. Drug delivering substance containing polyalkylene glycol and phospholipid covalently bonded to drug
AU2001268734A1 (en) 2000-06-28 2002-01-08 Merck & Co., Inc. Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
CA2450985A1 (en) 2001-06-28 2003-01-09 Mountain View Pharmaceuticals, Inc. Polymer stabilized proteinases
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
NZ543935A (en) 2003-05-12 2008-06-30 Affymax Inc Peptides that bind to the erythropoietin receptor
EA010015B1 (ru) 2003-05-12 2008-06-30 Афимакс, Инк. Новый разделительный фрагмент (спейсер) для модифицированных полиэтиленгликолем соединений на основе пептидов
WO2006005058A2 (en) * 2004-06-30 2006-01-12 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
SG2014009484A (en) * 2005-04-11 2014-05-29 Savient Pharmaceuticals Inc A variant form of urate oxidase and use thereof
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
NZ562292A (en) 2005-04-11 2009-11-27 Savient Pharmaceuticals Inc Variant forms of urate oxidase and use thereof
WO2006121995A2 (en) 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
JP5033177B2 (ja) * 2006-04-12 2012-09-26 サビエント ファーマセウティカルズ インク． 陽イオン界面活性剤によるタンパク質の精製
JP4890132B2 (ja) * 2006-07-20 2012-03-07 東洋紡績株式会社 ウリカーゼの比活性を向上させる方法、および比活性の向上した改変型ウリカーゼ
RU2382048C1 (ru) * 2008-12-25 2010-02-20 Общество С Ограниченной Ответственностью "Фармапарк" Лекарственное средство на основе модифицированного интерферона альфа с пролонгированным терапевтическим действием
NZ597089A (en) 2009-06-25 2014-05-30 Savient Pharmaceuticals Inc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
AU2011299153B2 (en) 2010-09-10 2014-10-30 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
CN102634492B (zh) 2011-02-14 2015-06-10 重庆富进生物医药有限公司 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用
EP2833883A4 (en) 2012-04-06 2015-12-23 Indus Pharmaceuticals Inc NOVEL COMPOSITIONS OF COMBINATIONS OF NONCOVALENT DNA BINDER AND CANCER-INHIBITING AND / OR INFLAMMATORY ACTIVE SUBSTANCES AND THEIR USE IN THE TREATMENT OF ILLNESSES
MX380164B (es) 2013-05-03 2025-03-12 Selecta Biosciences Inc Uso de una macromolécula terapéutica y una composición que comprende nanoportadores sintéticos que se unen a inmunosupresores para reducir la hipersensibilidad tipo i y tipo iv en un sujeto.
CA2984926A1 (en) 2015-05-15 2016-11-24 Medimmune, Llc Improved uricase sequences and methods of treatment
CN105412942B (zh) * 2015-12-23 2019-02-26 沈阳三生制药有限责任公司 聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂
WO2018089808A1 (en) 2016-11-11 2018-05-17 Horizon Pharma Rheumatology Llc Combination therapies of prednisone and uricase molecules and uses thereof
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
WO2018169811A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
CN112980808B (zh) * 2019-12-12 2024-10-29 深圳迈瑞生物医疗电子股份有限公司 尿酸酶、及其制备方法和用途
EP4240423A1 (en) 2020-11-03 2023-09-13 Protalix Ltd. Modified uricase and uses thereof
CN114438048B (zh) * 2020-11-05 2024-10-22 重庆派金生物科技有限公司 尿酸氧化酶制剂及其应用
CN114438047B (zh) * 2020-11-05 2024-11-22 重庆派金生物科技有限公司 制备聚乙二醇修饰的尿酸氧化酶的方法
JPWO2022172343A1 (cg-RX-API-DMAC7.html) 2021-02-10 2022-08-18
CN114181917B (zh) * 2022-02-14 2022-06-03 潍坊华卓生物科技有限公司 一种改造尿酸酶、基因序列、制备方法及应用
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6301M (cg-RX-API-DMAC7.html) * 1967-03-29 1968-09-09
US3616231A (en) * 1968-11-14 1971-10-26 Boehringer Mannheim Gmbh Process for the production of uricase
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6031472B2 (ja) * 1978-12-14 1985-07-22 協和醗酵工業株式会社 酸性ウリカ−ゼ
JPS55135590A (en) * 1979-04-05 1980-10-22 Mihama Hisaharu Modified asparaginase and uricase and their preparation
JPS57192435A (en) * 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
JPS6255079A (ja) * 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
NZ234453A (en) * 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
BRPI9912974B8 (pt) * 1998-08-06 2021-05-25 Univ Duke conjugados de peg-urato oxidase e seu uso
NZ509633A (en) * 1998-08-06 2003-04-29 Univ Duke A recombinant chimeric PEG-uricase with a long circulatory life and reduced immunogenicity
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates

Also Published As

Publication number Publication date
HUP0103003A3 (en) 2006-04-28
RU2246318C2 (ru) 2005-02-20
PL346224A1 (en) 2002-01-28
JP2002522399A (ja) 2002-07-23
HUP0103003A2 (hu) 2001-11-28
EP1100542B1 (en) 2005-06-22
JP2009254376A (ja) 2009-11-05
KR20040088585A (ko) 2004-10-16
CZ2001317A3 (cs) 2001-07-11
PL383331A1 (cg-RX-API-DMAC7.html) 2002-01-28
BRPI9917760B8 (pt) 2021-05-25
RU2006107111A (ru) 2007-09-20
KR100488848B1 (ko) 2005-05-11
JP5291235B2 (ja) 2013-09-18
HU226294B1 (en) 2008-08-28
PL202799B1 (pl) 2009-07-31
IL141220A0 (en) 2002-03-10
NZ509595A (en) 2004-02-27
JP2013039139A (ja) 2013-02-28
KR100614212B1 (ko) 2006-08-21
JP5183836B2 (ja) 2013-04-17
JP5290901B2 (ja) 2013-09-18
WO2000007629A3 (en) 2000-06-08
KR20010072287A (ko) 2001-07-31
RU2278680C2 (ru) 2006-06-27
BR9917760B1 (pt) 2014-11-25
RU2349341C2 (ru) 2009-03-20
CZ303751B6 (cs) 2013-04-24
EP1100542A2 (en) 2001-05-23
TW570981B (en) 2004-01-11
AU770014B2 (en) 2004-02-12
PL220873B1 (pl) 2016-01-29
WO2000007629A2 (en) 2000-02-17
HU228916B1 (en) 2013-06-28
IL183948A (en) 2010-11-30
BR9912974A (pt) 2001-05-08
IL141220A (en) 2007-09-20
IL183948A0 (en) 2007-10-31
BRPI9912974B1 (pt) 2015-08-25
AU5251599A (en) 2000-02-28
RU2004104953A (ru) 2005-07-27

Similar Documents

Publication Publication Date Title
BRPI9912974B8 (pt) conjugados de peg-urato oxidase e seu uso
DK2158923T3 (da) Peg-uratoxidase-konjugater og anvendelse deraf
TR200101400T2 (tr) 2-Fenilbenzimidazoller ve 2-fenilindoller, hazırlanmaları ve kullanımları
PL350658A1 (en) Medical preparations for the treatment of alpha−galactosidase a deficiency
MX9709472A (es) & -amilasa mutante.
NZ504258A (en) Exendin 3 and 4 agonist compounds for the treatment of diabetes
AU5624699A (en) Use of 5ht-6 antagonists
AU2001291687A1 (en) Polyammonium-polysiloxane compounds, methods for the production and use thereof
BR9909129A (pt) Conjugados de proteases
BR9910251A (pt) Estimulação hematopoiética
AU2002335133A1 (en) Polyether ester elastomer comprising polytrimethylene ether ester soft segment and tetramethylene ester hard segment
BR9815332A (pt) Dispositivo absorvente inserìvel no espaço interlabial de uma usuária feminina
ITMI911757A1 (it) Miscele di polisaccaridi di bassi pesi molecolari, procedimento di preparazione e impiego.
DE60016603D1 (de) Blattfedergelenk
BR0112461A (pt) Composições que contém componentes terapeuticamente ativos tendo uma solubilidade aumentada
BR0009964A (pt) Peptìdios artificiais com atividade desuperfìcie e sua utilização na preparação de surfactante artificial
DE69915693D1 (de) 2,5-diazabicyclo(2.2.1)heptanderivate, deren herstellung und deren verwendung in heilkunde
ATE234108T1 (de) Therapeutikum zur unterdrückung von schnarchgeräuschen
MY127047A (en) Disposable diaper
DE69531285D1 (de) Verwendung von polyethylenoxid enthaltenden polymerisierten quaternären ammoniumverbindungen in pharmazeutischen präparaten
WO2002074344A3 (en) Peg-conjugates of hgt-nk4
IT1306088B1 (it) Guida idrostatica con modalita' di funzionamento sia reattive che nonreattive.
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
MXPA03004539A (es) Luciferasas aisladas y uso de las mismas.
CA2135739A1 (en) Hemoglobin-Enzyme Complexes

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/08/2015, OBSERVADAS AS CONDICOES LEGAIS.

B15K Others concerning applications: alteration of classification

Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: A61K 47/48; A61K 38/44; C12N 9/06.

Ipc: C12N 9/06 (2006.01), A61K 47/60 (2017.01), A61K 38

Ipc: C12N 9/06 (2006.01), A61K 47/60 (2017.01), A61K 38

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/08/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 02/08/2019